%0 Journal Article
%T Combined Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 Reduces Molnupiravir-Induced Mutagenicity and Prevents Selection for Nirmatrelvir/Ritonavir Resistance Mutations.
%A Zhou S
%A Long N
%A Rosenke K
%A Jarvis MA
%A Feldmann H
%A Swanstrom R
%J J Infect Dis
%V 0
%N 0
%D 2024 Jul 8
%M 38973065
%F 7.759
%R 10.1093/infdis/jiae213
%X We investigated the mutation profiles of severe acute respiratory syndrome coronavirus 2 in samples collected from a molnupiravir and nirmatrelvir/ritonavir combination therapy in macaques. We found that molnupiravir induced several nirmatrelvir resistance mutations at low abundance that were not further selected in combination therapy. Coadministration of nirmatrelvir/ritonavir lowered the magnitude of the mutagenetic effect of molnupiravir.